Antisoma Announces Positive ASA404 Presentations at ASCO
LONDON, May 30, 2008 - Antisoma (LSE:ASM; USOTC:ATSMY) announces today details of two presentations on ASA404 that will be made at the upcoming 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO):
Abstract no. 8072 (poster) Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404); M. J. McKeage, M. B. Jameson, AS1404-201 Study Group Investigators; on Sunday 1 June, 2-6pm - Board 45c, in S Hall A1.
Abstract no. 5007 (oral presentation) Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study; R. Pili, M. Rosenthal, AS1404-203 study group investigators; on Monday 2 June, 11.30-11.45am in Clinical Science Symposium on 'Novel antiangiogenic mechanisms' in Room W375a.
Enquiries: Glyn Edwards, CEO Daniel Elger, Director of Communications +44 (0)7909 915 068 Antisoma plc
Mark Court/Lisa Baderoon/Rebecca Skye +44 (0)20 7466 5000 Dietrich Buchanan Communications
Brian Korb +1 646 378 2923 The Trout Group
Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the company's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.
Background on ASA404 ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) which targets the blood vessels that nourish tumours. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001. Worldwide rights to the drug were licensed to Novartis AG in April 2007. A phase III trial (ATTRACT-1) is evaluating ASA404 in combination with carboplatin and paclitaxel in the first-line treatment of non-small cell lung cancer.
Background on Antisoma Headquartered in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma.
Posted: May 2008
